Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging - Wikidata - wikimedia - TriplyDB

Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging

Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging

http://www.wikidata.org/entity/Q34502985

about

High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy.Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical model Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy.Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.Durable antitumor responses to CD47 blockade require adaptive immune stimulation.A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.Molecular Imaging of Immunotherapy Targets in Cancer.PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy.Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy.Monitoring immune-checkpoint blockade: response evaluation and biomarker development.PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers.Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015).Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies.Noninvasive monitoring of cancer therapy induced activated T cells using [18F]FB-IL-2 PET imaging.Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model.PD-L1 is an activation-independent marker of brown adipocytes.Identification and characterization of a novel Sso7d scaffold-based binder against Notch1.Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies.Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography?Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant.High-affinity human PD-L1 variants attenuate the suppression of T cell activation.Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab.Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy.Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors.The Positive Relationship Between γH2AX and PD-L1 Expression in Lung Squamous Cell Carcinoma.Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with Zirconium 89 in Human Lymphoma Xenografts.Combination therapy for cancer with oncolytic virus and checkpoint inhibitor: A mathematical model.Rapid PD-L1 detection in tumors with PET using a highly specific peptide.Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response.Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma.High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2 Defining and Understanding Adaptive Resistance in Cancer Immunotherapy

P2860

Q27300777-196A7B90-AF41-4E05-ABE9-CF66594DB6D2 Q28075712-5514C7AA-DFA2-43A6-937F-9453ABC49B56 Q29964482-6B55DEB9-879F-48C4-A18E-DFA11257FCD8 Q33728672-8FE58EAC-57C3-4B23-B2DD-774B895A5435 Q33850467-FF19128D-2912-49C7-9A2C-FF14939BED5F Q33912075-00C96C1A-B8C2-458F-931B-705B54FEA632 Q36904867-7C4DA57D-2B56-4D50-940E-ACCD24ED9CB3 Q36962925-4BC30A94-1492-44D9-A4D1-B3D5D61B196F Q37309882-6A1BC175-8FE1-42FC-88BC-5987A784A5D7 Q37621295-EFD9B1D5-E584-4C10-831B-C3960D8C1F0C Q37714274-8FFBD800-9599-44C0-A455-F960079B0114 Q37722443-406F5A37-6573-4CF6-A26D-307A58279796 Q38666241-454B7E33-03A3-44FF-9117-2B312EA85118 Q38703214-428D0E71-E0A0-47AC-81A1-525C829E1A1B Q38726053-F7119C78-8676-4C85-B907-DE806D2EE9EF Q38836740-C7DF66C5-8881-48CE-AEFF-25819BCB5891 Q38883319-E70AF894-EC24-43AC-92AC-23FE895173F9 Q38999322-18C34217-DA2A-476B-A8FE-103F02ECB26B Q40336066-A932CCB2-707C-42B0-9C92-7E39F7F60C64 Q41064188-05805F13-DD50-41F3-A782-70DF5425424B Q41693775-4F2DD900-971F-46D3-9C08-E0FB8EBD93BF Q41696862-5B2D8C71-867B-4C56-9191-66237888827E Q41849636-46391E93-B672-4BE3-8124-3DD89C2386C8 Q42318752-1DF2E927-18BB-46EB-BBCF-3F039B66A0F2 Q42387009-7DF5FA7C-3949-4578-89CD-CB6E1C8AF3A7 Q47123123-D39B73B5-7DBC-4127-89DE-417FB8F79E28 Q47783661-5DB1CFC8-9728-4B80-B43F-F0E518DA1099 Q47962563-FF10AEBF-ECC4-4147-B95D-F8145BED6DC7 Q48227716-5CE61D59-2D16-4D55-A595-B05A4A804BF8 Q49593980-9A5F219C-B511-4C48-82AD-05E5566F41FE Q49953473-454D27C5-16D1-4DCA-83C9-9A08525FF559 Q50053595-0E4FDE2F-313C-4852-9D16-90B5FDFBF3AE Q51234651-D7807E3E-49DE-4FE6-8E32-192F0075DEA2 Q52874301-DEEDB896-D626-47AA-99D8-6D9A939D139F Q55224585-95918A4E-2E93-4071-97C1-33EE1FC997CB Q56888862-C6FA5105-D7F0-45A4-8B2C-FC28F9CFC967 Q57173769-D70043C4-7AD3-453F-8245-827190B4B781

P2860

Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging

http://www.wikidata.org/entity/Q34502985

description

2015 nî lūn-bûn

@nan

2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Engineering high-affinity PD-1 ...... therapy and immuno-PET imaging

@ast

Engineering high-affinity PD-1 ...... therapy and immuno-PET imaging

@en

Engineering high-affinity PD-1 ...... therapy and immuno-PET imaging

@nl

type

label

Engineering high-affinity PD-1 ...... therapy and immuno-PET imaging

@ast

Engineering high-affinity PD-1 ...... therapy and immuno-PET imaging

@en

Engineering high-affinity PD-1 ...... therapy and immuno-PET imaging

@nl

prefLabel

Engineering high-affinity PD-1 ...... therapy and immuno-PET imaging

@ast

Engineering high-affinity PD-1 ...... therapy and immuno-PET imaging

@en

Engineering high-affinity PD-1 ...... therapy and immuno-PET imaging

@nl

P1433

Q34502985-D73CC1B3-267D-4224-A985-66A2643247D7

P1476

Q34502985-743C9394-4338-43AD-91C6-DDB604A08853

P2093

Q34502985-19C50C9C-E6A4-4B19-94D3-93D4AF0E24AA

Q34502985-27AB2E6A-2492-4267-A2C3-CF2C2C1E2434

Q34502985-35BCA450-D35C-4AB9-A047-41B252444482

Q34502985-428E3C93-05C1-4508-8232-F4C67D35DF3D

Q34502985-4831E316-11ED-478A-A552-C91F2563DADF

Q34502985-7B234F0F-2517-4839-BD68-1873F63E4640

Q34502985-8BC8E6F5-47DD-4379-B3B7-94A08D141F80

Q34502985-A9385780-6CB9-451C-A0E6-193AAD85F4E4

Q34502985-AB9DDF5F-F35B-4493-911A-934A84D16258

Q34502985-B67CAB0F-A7A0-4480-9197-58A67BE9F11D

P2860

Q34502985-0242365C-E4DD-4D87-AE2B-5820E99A8BE5

Q34502985-1352384F-5BD3-43A5-B320-5F9B38DA424A

Q34502985-1E6F7C30-D589-49A6-B418-731704047596

Q34502985-2FBF0517-BC07-4814-BB45-04888801CD8A

Q34502985-3D764CD7-18E2-4BAC-BF04-67C1363897D1

Q34502985-51120082-3C7E-48A4-A14E-4E0FE49D549B

Q34502985-575AC59E-3D21-4D47-8177-F33FD8B86FF7

Q34502985-5EC8EEB9-8184-4DA2-803A-4060BC1ED505

Q34502985-747C5744-F768-4D37-A4B5-D88AC5800258

Q34502985-82CA3446-2969-4E21-A7DE-B620C3CBAB68

P304

Q34502985-B6B25D22-CED4-4E61-AE6F-31DC109BAB91

P31

Q34502985-6A720999-4C30-4EA2-B8B9-CA80FD2BB707

P356

Q34502985-637C4FF1-44BF-403B-AE03-1AD0B0C474A6

P407

Q34502985-F96DC2B6-2BDA-4F10-83B1-1671D256F5A4

P433

Q34502985-51568BD9-669E-4083-BFBB-38AE47942E26

P478

Q34502985-FBAA572E-B4D6-45E0-AC9A-379A1CF6036B

P50

Q34502985-FB55CA1B-F97E-405E-AE82-BF0EC6A3348A

P577

Q34502985-E7EBD850-C7DA-425F-89E8-8638544AD069

P5875

Q34502985-633D2F0B-5AE9-45C7-890A-078DF8FA0C4B

P698

Q34502985-6E242BDB-8331-4073-B12E-85861F5BD1A1

P921

Q34502985-74353B4F-C6DF-47A0-B1D0-625FF951C386

P932

Q34502985-B2E75398-73AE-4DDA-968B-5302BA93F8A6

P356

PNAS.1519623112

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Engineering high-affinity PD-1 ...... therapy and immuno-PET imaging

@en

P2093

Aaron M Ring

http://www.w3.org/2001/XMLSchema#string

Aaron T Mayer

http://www.w3.org/2001/XMLSchema#string

Andrew C Kruse

http://www.w3.org/2001/XMLSchema#string

Arutselvan Natarajan

http://www.w3.org/2001/XMLSchema#string

Irving L Weissman

http://www.w3.org/2001/XMLSchema#string

Jonathan M Tsai

http://www.w3.org/2001/XMLSchema#string

Melissa N McCracken

http://www.w3.org/2001/XMLSchema#string

Nan Guo Ring

http://www.w3.org/2001/XMLSchema#string

Richard Kimura

http://www.w3.org/2001/XMLSchema#string

Roy L Maute

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

The PD-1 pathway in tolerance and autoimmunity

The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors

Structure and Interactions of the Human Programmed Cell Death 1 Receptor

Adrenaline-activated structure of β2-adrenoceptor stabilized by an engineered nanobody

Nivolumab plus ipilimumab in advanced melanoma.

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

P304

E6506-14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1519623112

http://www.w3.org/2001/XMLSchema#string

P407

P433

47

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

Aashish Manglik

P577

2015-11-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283684560

http://www.w3.org/2001/XMLSchema#string

P698

26604307

http://www.w3.org/2001/XMLSchema#string

P921

P932

4664306

http://www.w3.org/2001/XMLSchema#string